Size of protein aggregates, not abundance, drives spread of prion-based disease

October 28, 2010

Mad Cow disease and its human variant Creutzfeldt-Jakob disease, which are incurable and fatal, have been on a welcome hiatus from the news for years, but because mammals remain as vulnerable as ever to infectious diseases caused by enigmatic proteins called prions, scientists have taken no respite of their own. In the Oct. 29 edition of the journal Science, researchers at Brown University report a key new insight into how prion proteins — the infectious agents — become transmissible: In yeast at least, it is the size of prion complexes, not their number, that determines their efficiency in spreading.

"The dogma in the field was that the misfolding of the protein is sufficient to cause disease, and the clinical course of the infection depended on the amplification of the misfolded protein," said Tricia Serio, associate professor of molecular biology, cell biology and biochemistry. "But over the years in mammals it has become clear that the abundance of misfolded protein is not a good predictor of disease progression. The question is, What else has to happen for you to get the clinical pathology?"

Cells make prion proteins naturally, although biologists do not understand what their normal role is in mammals. When those proteins misfold in cells, they assemble into structures called aggregates, but other proteins, known as chaperones, attempt to break down the aggregates. The rates at which this assembly and disassembly occurs are determined by the shape or conformation that the has adopted.

"Different conformations of the same prion protein can dramatically alter the spread of pathology and the incubation time of prion diseases," Serio said. "We wanted to learn how."

By combining experiments in yeast cells with mathematical models, the Brown team found that what affects a prions' ability to transmit from cell to cell is the size of the structures into which they assemble, Serio said. If the aggregates become too large, they lose their transmissibility among cells. Prion aggregates that remain small are transmitted with greater efficiency.

"In this paper we changed the transmissibility just by shifting the size," Serio said. "We could change it in either direction."

The proof was plain to see. Postdoctoral researcher Aaron Derdowski monitored differently sized prion aggregates as they moved among cells under the microscope and could see that smaller ones fared better than larger ones. He also kept track of the spread of different prion structures through a genetic analysis of affected cell populations.

In concert with the experimental work, Suzanne Sindi, a postdoctoral researcher with a joint appointment in molecular biology, cell biology and biochemistry and the Center for Computational Molecular Biology, modeled how cells make and spread prion aggregates, providing a novel simulation of the process that she ran on a computing cluster in the Center for Computation and Visualization at Brown. The model that best replicated experimental observations was the one in which aggregate size, rather than abundance, was the key factor.

Implications for disease

Serio says the insights the team has gained in yeast may better explain what others have observed in mammals as well.

"Previously it was not clear why you would have those outcomes," she said.

Ultimately the findings could inform future strategies for developing a treatment for prion infection. If researchers unaware of the importance of aggregate size developed a therapy to hinder aggregate formation, they might inadvertently make things worse by producing smaller aggregates, Serio said.

"A more effective strategy might be to control the size of the aggregates," she said, "rather than their presence or absence."

The findings may also relate to other neurodegenerative diseases that depend on misfolding proteins, such as Alzheimer's disease or Parkinson's disease, Serio said.

Related Stories

Recommended for you

Engineered protein treatment found to reduce obesity in mice, rats and primates

October 19, 2017
(Medical Xpress)—A team of researchers with pharmaceutical company Amgen Inc. report that an engineered version of a protein naturally found in the body caused test mice, rats and cynomolgus monkeys to lose weight. In their ...

New procedure enables cultivation of human brain sections in the petri dish

October 19, 2017
Researchers at the University of Tübingen have become the first to keep human brain tissue alive outside the body for several weeks. The researchers, headed by Dr. Niklas Schwarz, Dr. Henner Koch and Dr. Thomas Wuttke at ...

Cancer drug found to offer promising results in treating sepsis in test mice

October 19, 2017
(Medical Xpress)—A combined team of researchers from China and the U.S. has found that a drug commonly used to treat lung cancer in humans offers a degree of protection against sepsis in test mice. In their paper published ...

Tracing cell death pathway points to drug targets for brain damage, kidney injury, asthma

October 19, 2017
University of Pittsburgh scientists are unlocking the complexities of a recently discovered cell death process that plays a key role in health and disease, and new findings link their discovery to asthma, kidney injury and ...

Study reveals key molecular link in major cell growth pathway

October 19, 2017
A team of scientists led by Whitehead Institute has uncovered a surprising molecular link that connects how cells regulate growth with how they sense and make available the nutrients required for growth. Their work, which ...

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.